Literature DB >> 32086781

Effect of Time to Surgery of Colorectal Liver Metastases on Survival.

Emerson Y Chen1, Skye C Mayo2, Thomas Sutton2, Matthew R Kearney3, Adel Kardosh3, Gina M Vaccaro3, Kevin G Billingsley2, Charles D Lopez4.   

Abstract

PURPOSE: Resection of liver-only colorectal liver metastases (CRLM) with perioperative chemotherapy is potentially curative. Specific primary tumor and liver metastasis characteristics have been validated to estimate the risk of recurrence. We hypothesize that the time interval from diagnosis of CRLM to surgery, or time to surgery (TTS), is clinically prognostic.
METHODS: Patients from a prospectively maintained institutional database at a Comprehensive Cancer Center from May 2003 to January 2018 were reviewed. Clinicopathologic, perioperative treatment, and TTS data were collected. TTS was categorized into short (< 3 months), intermediate (3-6 months), and long (> 6 months) intervals.
RESULTS: Two hundred eighty-one patients were identified. While overall survival (OS) was similar across TTS, postoperative overall survival (postoperative OS) of long TTS was associated with worse survival, 44 months (95% CI, 34-52) compared to short TTS, 59 months (95% CI, 43-79), and intermediate TTS, 63 months (95% CI, 52-108), both p < 0.01. With regard to long-term OS, intermediate TTS had 5-year OS of 59% and 8-year OS of 43% compared to long TTS (5-year OS 53% and 8-year OS 18%) and short TTS (5-year OS 54% and 8-year OS 29%). Long TTS was negatively associated with postoperative OS on multivariate analysis (HR 1.6, p < 0.01) when adjusting for resection margin, CRLM size, age, and use of postoperative chemotherapy.
CONCLUSION: Short and intermediate TTS had similar survival although patients with intermediate TTS may have better odds of long-term OS. While long TTS was associated with worse survival, likely due to higher disease burden, long-term survivors were still observed.

Entities:  

Keywords:  Chemotherapy; Clinical risk score; Colorectal cancer; Colorectal liver metastases; Time to surgery

Mesh:

Year:  2021        PMID: 32086781      PMCID: PMC7900034          DOI: 10.1007/s12029-020-00372-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  25 in total

1.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

2.  Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases.

Authors:  Lydia G M van der Geest; Jorine't Lam-Boer; Miriam Koopman; Cees Verhoef; Marloes A G Elferink; Johannes H W de Wilt
Journal:  Clin Exp Metastasis       Date:  2015-04-22       Impact factor: 5.150

Review 3.  First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Authors:  Elena Elez; Guillem Argilés; Josep Tabernero
Journal:  Curr Treat Options Oncol       Date:  2015-11

4.  Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?

Authors:  Srinevas K Reddy; Allan Tsung; James Wallis Marsh; David A Geller
Journal:  J Surg Oncol       Date:  2011-08-12       Impact factor: 3.454

5.  Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy.

Authors:  Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

6.  Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?

Authors:  John M Creasy; Eran Sadot; Bas Groot Koerkamp; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Vinod P Balachandran; T Peter Kingham; Ronald P DeMatteo; Peter J Allen; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  Surgery       Date:  2018-02-15       Impact factor: 3.982

7.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

8.  Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.

Authors:  David J Gallagher; Junting Zheng; Marinela Capanu; Dana Haviland; Philip Paty; Robert P Dematteo; Michael D'Angelica; Yuman Fong; William R Jarnagin; Peter J Allen; Nancy Kemeny
Journal:  Ann Surg Oncol       Date:  2009-02-18       Impact factor: 5.344

9.  Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.

Authors:  Tomoyuki Kato; Kenzo Yasui; Takashi Hirai; Yukihide Kanemitsu; Takeo Mori; Kenichi Sugihara; Hidetaka Mochizuki; Junji Yamamoto
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

10.  Patterns of metastasis in colon and rectal cancer.

Authors:  Matias Riihimäki; Akseli Hemminki; Jan Sundquist; Kari Hemminki
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

View more
  2 in total

1.  Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study.

Authors:  Benjamin Gravesteijn; Eline Krijkamp; Jan Busschbach; Geert Geleijnse; Isabel Retel Helmrich; Sophie Bruinsma; Céline van Lint; Ernest van Veen; Ewout Steyerberg; Kees Verhoef; Jan van Saase; Hester Lingsma; Rob Baatenburg de Jong
Journal:  Value Health       Date:  2021-03-05       Impact factor: 5.725

2.  Ruscogenin attenuated tight junction injury and tumor migration in colorectal liver metastasis mice via regulating TRAP1.

Authors:  Yanni Lv; Xuehan Wu; Jin Chen; Feng Shao
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.